Connect Biopharma Holdings (CNTB) Enterprise Value (2021 - 2026)

Connect Biopharma Holdings has disclosed Enterprise Value across 6 years of filings, most recently posting $118.4 million for Q2 2026.

• In Q2 2026, Enterprise Value rose 784.2% year-over-year to $118.4 million; the TTM figure through Jun 2026 stood at $118.4 million (up 784.2% YoY), while the FY2025 annual figure was $114.8 million, up 761.79% from the prior year.
• Enterprise Value came in at $118.4 million for Q2 2026 at Connect Biopharma Holdings, roughly flat from $118.3 million in the prior quarter.
• In the past five years, Enterprise Value ranged from a high of $118.4 million in Q2 2026 to a low of -$146.1 million in Q2 2022.
• Average Enterprise Value over 5 years is $4.8 million, with a median of -$17.3 million recorded in 2024.
• Year-over-year, Enterprise Value tumbled 708.07% in 2022 and soared 784.2% in 2026.
• Over 5 years, Enterprise Value stood at -$101.4 million in 2022, then jumped by 47.44% to -$53.3 million in 2023, then surged by 67.44% to -$17.4 million in 2024, then surged by 761.79% to $114.8 million in 2025, then climbed by 3.08% to $118.4 million in 2026.
• Per Business Quant data, the three most recent Enterprise Value figures were $118.4 million in Q2 2026, $118.3 million in Q1 2026, and $114.8 million in Q4 2025.